Related Experiment Videos
Cytotoxic activity of a diptheria toxin/FGF6 mitotoxin on human tumour cell lines
P M Coll-Fresno1, M Batoz, S Tarquin
1Laboratoire d'Oncologie Moléculaire, Unité 119 de I'Institut Nationalde la Santé Et de la Recherche Médicale, Marseille, France.
Abstract:
The FGFs constitute a family of, at least, 12 polypeptides (FGF1 to FGF12) implicated in a number of physiological and pathological processes throughout embryogenesis and adult life. They bind to at least three types of cell surface molecules, including four high affinity transmembrane tyrosine kinase receptors (FGFR1 to FGFR4). In addition to important roles during development, FGF involvement in pathological conditions, including tumour formation, has been suspected, and overexpression of FGFR in tumour specimens is well documented. Diphtheria Toxin/FGF6 (DT/FGF6) mitotoxin has been shown to selectively and effectively target FGFR1-expressing cells. We show here that DT/FGF6 targets myoblasts engineered to express either one of the four FGFR, as well as FGFR-expressing tumour cells.
Insights
Fibroblast Growth Factors (FGFs) and their receptors (FGFRs) are vital in development and disease. A novel diphtheria toxin-FGF6 (DT/FGF6) conjugate effectively targets cells expressing FGFRs, including tumor cells.
Area of Science:
- Biochemistry
- Cell Biology
- Molecular Medicine
Background:
- Fibroblast Growth Factors (FGFs) are a family of 12+ polypeptides crucial for development and adult physiology.
- FGFs interact with cell surface molecules, notably four high-affinity tyrosine kinase receptors (FGFR1-4).
- FGFR overexpression is linked to pathological conditions like tumor formation.
Purpose of the Study:
- To investigate the targeting capabilities of the Diphtheria Toxin/FGF6 (DT/FGF6) mitotoxin.
- To determine if DT/FGF6 can selectively target cells expressing different FGFR subtypes.
- To assess the potential of DT/FGF6 as a therapeutic agent against FGFR-expressing tumors.
Main Methods:
- Engineering myoblasts to express individual FGFR subtypes (FGFR1-4).
- Treating engineered myoblasts and FGFR-expressing tumor cells with DT/FGF6.
- Evaluating the selective targeting and cytotoxic effects of DT/FGF6.
Main Results:
- DT/FGF6 demonstrated selective targeting of myoblasts engineered to express any of the four FGFRs.
- The mitotoxin effectively targeted FGFR-expressing tumor cells.
- These findings confirm the specificity and efficacy of DT/FGF6 against FGFR-expressing cells.
Conclusions:
- DT/FGF6 is a potent and selective agent for targeting cells expressing FGFR1-4.
- This conjugate holds promise for therapeutic applications in conditions characterized by FGFR overexpression, such as certain cancers.
- Further research into DT/FGF6 could lead to novel cancer therapies.